Neonatal Research Institute
Clinical Trial: Aerosolized Infasurf
Babies born prematurely do not have enough of a substance called surfactant, which helps keep their lungs fully expanded. This trial looks at a novel approach to delivering surfactant.
Clinical trial: Aerosolized Infasurf
Primary investigator: Dr. Anup Katheria
Research coordinator: Melissa Brown
About this trial.
Babies are currently given surfactant via a breathing tube inserted in the windpipe — called intubation. This trial will study a new method to aerosolize the liquid or turn it into a mist, which allows the baby to breathe spontaneously and does not require intubation.
This study will compare two methods of surfactant delivery: intubation and aerosolized. The aerosolized surfactant used in this study is Infasurf. Effective aerosolized delivery of Infasurf can potentially decrease the need for intubation — and decreasing the risks associated with the insertion of the tube.
The aim of the study is to determine if aerosolized Infasurf is a successful method of delivery and can potentially eliminate the need for intubation in some patients.
To learn more about the NICU at Sharp Mary Birch, visit Neonatal Intensive Care Unit. For more information about the Neonatal Research Institute or to learn more about our clinical trials, send us an email or call 858-939-4112.